Impacting society, creating change
Technologies developed at Ohio State are changing the world. Learn more about the startups that are currently a part of the Ohio State portfolio or download our printable catalog (as of June 30, 2019).
Search for a Startup below
ExoNanoRNA is commercializing a novel drug delivery system utilizing branched RNA nanostructures to improve drug solubility in vivo, drug loading efficiency, and drug efficacy while reducing toxicity and allowing for tumor targeting.
Entrada Therapeutics is developing an intracellular biologics and drug delivery platform designed to enable new treatments for devastating diseases. Entrada’s delivery vehicles boast improved bioavailability, biodistribution, metabolic stability and enhanced efficiency compared to previous gold standards. Initially the company will focus on utilizing its intracellular delivery system for treating a rare, fatal mitochondria disease with no currently approved treatment options.
CytoImmune Therapeutics is commercializing a coordinated immunotherapy platform for cancer treatments that combines chimeric antigen receptors (CARs) and bispecific antibodies (biAbs) with T cells and natural killer cells. This technology reduces the patient’s time to personalized treatment and enables optimized dosing with limited off-target effects. The company is developing product candidates targeted at treating acute myeloid leukemia, glioblastoma and multiple myeloma.
Celenex is a clinical-stage gene therapy company bringing to market a portfolio of ten gene therapies licensed from Nationwide Children’s Hospital and The Ohio State University for treatments for lysosomal storage disorders. The company is initially targeting Batten disease, with therapies targeting CLN6, CLN3 and CLN8, as potential first-to-market curative therapies for these rare and devastating diseases. Celenex was acquired by Amicus Therapeutics in September 2018 for $100M upfront and $277M in potential downstream milestone payments.
AveXis is a biotechnology company developing gene therapies designed to treat rare and life-threatening neurological genetic diseases. The initial proprietary investigational gene replacement therapy, AVXS-101 (onasemnogene abeparvovec-xioi) is in development for the treatment of spinal muscular atrophy (SMA). In addition, the company is pursuing gene therapies for Rett syndrome (AVXS-201) and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene (AVXS-301).